Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
109.07
+4.17 (3.98%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 104.59 - 109.72
52 week 63.47 - 140.00
Open 104.59
Vol / Avg. 723,192.00/731,778.00
Mkt cap 9.23B
P/E     -
Div/yield     -
EPS -2.32
Shares 84.62M
Beta 1.95
Inst. own 79%
Nov 3, 2015
Q3 2015 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 9, 2015
Alnylam Pharmaceuticals Inc at FBR Healthcare Conference Add to calendar
Aug 30, 2015
Medicines Co and Alnylam Pharmaceuticals Inc Conference Call to Discuss Initial ALN-PCSsc Phase 1 Clinical Results - 9:30AM EDT - Add to calendar
Aug 20, 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: Patisiran and Revusiran for the treatment of Transthyretin (TTR)-Mediated Amyloidosis - Webcast
Aug 14, 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-AAT for the treatment of AAT Deficiency-associated liver disease - Webcast
Aug 12, 2015
Alnylam Pharmaceuticals Inc at Canaccord Genuity Growth Conference
Aug 6, 2015
Q2 2015 Alnylam Pharmaceuticals Inc Earnings Call
Aug 6, 2015
Q2 2015 Alnylam Pharmaceuticals Inc Earnings Release
Jul 28, 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-HBV for the treatment of Hepatitis B Virus (HBV) Infection - Webcast
Jul 23, 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-CC5 for the treatment of Complement-Mediated Diseases
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -826.52% -712.79%
Operating margin -839.88% -800.97%
EBITD margin - -777.39%
Return on average assets -18.23% -48.05%
Return on average equity -19.82% -59.74%
Employees 256 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company’s pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Officers and directors

John K. Clarke Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President - General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
David-Alexandre Gros Senior Vice President, Chief Business Officer
Age: 42
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 40
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 56
Bio & Compensation  - Reuters
Amy W. Schulman Director
Age: 54
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters